Phase I Study: Quotient Code QSC303294
This is an early research study, called a Phase 1 trial, focused on a new medicine known as QSC303294. These kinds of trials are the very first step in testing a new treatment in people, usually healthy volunteers. The main goals are to make sure the medicine is safe and to understand how the body handles it, including how much can be given without causing serious side effects. For this particular study, we are looking for healthy adults between 18 and 55 years old, of any gender. At this stage, not all the details about the medicine or what taking part will involve can be shared publicly due to the early nature of the research. However, full information will be made available within 30 months after the study has officially finished. This careful approach helps protect proprietary information while still ensuring transparency in due course.
At a glance
What is this study about?
This research study, known as 'Quotient Code QSC303294', is a very early step in developing a potential new medicine. It's called a Phase 1 trial, which means it's one of the first times this new medicine is being tested in people. The main purpose of these early studies is to check if the medicine is safe and to understand how it behaves in the human body. Researchers will be looking at things like how much of the medicine stays in the body, how it's processed, and if there are any side effects. These studies are crucial because they help determine if a new treatment can move forward to larger trials.
Because this is such an early stage of development, the detailed information about the medicine and the exact procedures of the study are not yet fully available to the public. This is a common practice to protect the new discovery while the research is ongoing. The organisation running the study has made a plan to share all the full details within 30 months after the study has officially come to an end. This ensures that eventually, all the information will be accessible.
Understanding these early trials is important because they lay the groundwork for future medical advancements. Every new medicine that eventually helps people has to start with these careful, small-scale safety checks. While details are limited now, the commitment to publish them later means that the scientific community and the public will eventually have a complete picture of this research.
Key takeaways
- This is an early-stage (Phase 1) study for a new medicine, QSC303294.
- The main goals are to check for safety and how the medicine works in the body.
- It's open to healthy volunteers aged 18 to 55, both men and women.
- Full study details will be released in roughly 2.5 years after it finishes.
- Participation involves close medical monitoring.
Who may be eligible?
This study is looking for healthy adults. To be considered, you must be between 18 and 55 years old.
Both men and women are welcome to take part in this research.
While the full specific health requirements for who can and cannot join aren't publicly available yet, generally, for early-stage studies like this, volunteers are expected to be in good overall health. This means you likely shouldn't have any significant ongoing illnesses or be taking certain medications that could interfere with the study medicine.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 55 years old?
- Are you generally healthy?
- Are you, or could you be, male or female?
- Are you interested in helping medical research?
What does participation involve?
Due to the early stage of this research (Phase 1), the full details about what taking part would involve are not yet public. However, typically in a Phase 1 study, participants would likely need to have several visits to a clinic or research unit. These visits often include checks like blood tests, heart readings (ECGs), and monitoring of your overall health.
You would be given the study medicine, probably in a controlled environment, and then carefully watched for any effects or changes. The number of doses, how they are given (e.g., as a tablet or injection), and the total length of time you'd be involved (including follow-up appointments after you stop taking the medicine) are part of the detailed information that will be released later. It’s common for these studies to involve an overnight stay or multiple visits over several weeks.
Potential risks and benefits
Locations (1)
- Quotient Sciences LimitedCity onlyNottingham, England
Common questions
What is a Phase 1 study?
A Phase 1 study is the first stage of testing a new medicine in people, usually healthy volunteers. Its main purpose is to check for safety and how the body handles the medicine.
Why aren't all the details available now?
Because this is an early-stage study, some details are kept private to protect the new medicine and research. Full information will be shared within 30 months after the study finishes.
Who can take part in this study?
We are specifically looking for healthy adults aged between 18 and 55 years old. Both men and women are welcome.
Will I get the actual medicine?
Yes, in a Phase 1 study, participants receive the new medicine so researchers can observe its effects and safety under careful monitoring.
What happens after the study ends?
All the results and detailed information from the study will be made public within 30 months after the study is officially completed.
How to find out more
Gonçalo Cordeiro
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.